1.	Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UMCNONCO200801, NCT00777504
2.	Biological, Pathological and Imagery Markers in the First-Line Treatment of Metastatic Clear-Cell Renal Cell Carcinoma Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: P070104, NCT00930345
3.	Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients Phase: Phase IV Type: Natural history/Epidemiology Status: Active Age: 18 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: A6181118, NCT01073644
4.	Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan) Phase: Phase IV Type: Natural history/Epidemiology Status: Active Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: 3066K5-4406, B1771015, NCT01210482
5.	An Open Label, Single Arm Trial to Characterize Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2) Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CRAD001LDE36T, 2010-021370-11, NCT01266837
6.	Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney Cancer Phase: Phase IV Type: Natural history/Epidemiology Status: Approved-not yet active Age: Any age Sponsor: Pharmaceutical / Industry Protocol IDs: 15246, NX0913IN, NCT01353794
7.	Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: SG 327/10, NCT01402089
8.	The Use of Self Retaining Sutures in Open and Laparoscopic Partial Nephrectomy Phase: Phase IV Type: Supportive care Status: Approved-not yet active Age: No age specified Sponsor: Other Protocol IDs: Dalhousieurosrs-2011, NCT01413607
9.	Temsirolimus (Torisel) Special Investigation (Regulatory Post Marketing Commitment Plan) Phase: Phase IV Type: Natural history/Epidemiology Status: Active Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: B1771016, NCT01420601
10.	Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001LDE43, 2011-003416-23, NCT01514448
11.	First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and ove Sponsor: Other Protocol IDs: iOM-605, 2011-001138-40, NCT01521715
12.	SU011248 versus Interferon-alfa as First-Line Systemic Therapy for Patients with Metastatic Renal Cell Carcinoma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A6181034, UCLA-0406015-01, PFIZER-A6181034, NCT00083889
13.	A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A6181109, NCT00375674
14.	Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer Phase: Phase III Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: MRC-RE05-SORCE, MRC-RE05-SORCE, EUDRACT ID 2006-006079-19, EU-20734, NCT00492258, SORCE, ISRCTN38934710
15.	Trial of Collagen Mesh for Prevention of Ventral Hernia After Surgery for Advanced Pelvic Cancer Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: VRAM M-20070240, NCT00647569
16.	Exercise for Patients With Renal Cell Cancer Receiving Sunitinib Phase: Phase III Type: Supportive care Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: SUIR8687, NCT00869011
17.	Clinical Trial to Assess the Importance of Nephrectomy Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: P070144, NCT00930033
18.	Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Phase: Phase III Type: Tissue collection/Repository, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000668388, SWOG-S0931, S0931, NCT01120249
19.	Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: EORTC-30073, EU-21022, PFIZER-EORTC-30073, NCT01099423
20.	Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-90802, CALGB-90802, NCT01198158
21.	Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CTKI258A2302, 2009-015459-25, NCT01223027
22.	Renal Cell Carcinoma (RCC) Scramble Phase: Phase III Type: Diagnostic Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2009-0845, NCT01224288
23.	A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 113387, NCT01235962
24.	Caphosol in Oral Mucositis Due to Targeted Therapy Phase: Phase III Type: Supportive care Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: Esperanz-002, NCT01265810
25.	Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma Phase: Phase III Type: Treatment Status: Active Age: 20 to 80 Sponsor: Other Protocol IDs: CROSS-J-RCC, UMIN000003040, NCT01481870